



22ND ANNUAL MEETING
FRIDAY, OCTOBER 11, 2013
MARRIOTT MARQUIS
SAN FRANCISCO, CALIFORNIA

INTERNATIONAL SOCIETY FOR ANAESTHETIC PHARMACOLOGY
SYLLABUS

6737 W Washington St, Suite 1300 • Milwaukee, Wisconsin 53214
(P) 414-755-6296 • (F) 414-276-7704 • www.isaponline.org • isaphq@isaponline.org

MISSION STATEMENT

The **International Society for Anaesthetic Pharmacology (ISAP)** is a nonprofit organization with an international membership, which is dedicated to teaching and research about clinical pharmacology in anesthesia, with particular reference to anesthetic drugs.

ACCREDITATION INFORMATION

Target Audience

This program is designed for an international audience of general anesthesiologists, pharmacological anesthesiologists, technology anesthesiologists and specialty physicians.

Practice Gaps

- Education in proper drug delivery for both physicians and other health care providers
- Contemporary knowledge in newer drugs that are coming to market and updates on new and old drugs with instruction on optimal delivery
- Education on drug development and when new drugs may come to market

Learning Objectives

- Review new developments in mechanisms of anaesthetic toxicity in various settings such as pre- and post-operative effects and related dysfunctions
- Discuss pharmacologic perspectives on commonly held beliefs in anaesthetic dogma. Topics will include a review of drug development from scientific processes to regulation of products pre and post introduction to the marketplace
- Review innovations in AIMS systems and how they interact with various anaesthetic agents while attempting to improve outcomes and patient safety

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council For Continuing Medical Education (ACCME) through the joint sponsorship of the International Anesthesia Research Society (IARS) and the International Society for Anaesthetic Pharmacology (ISAP). The IARS is accredited by the ACCME to provide continuing medical education for physicians. The International Anesthesia Research Society designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

The IARS complies with ACCME Essential Areas, Standards and Policies regarding industry support of CME Activities. The IARS has implemented policies and practices with respect to the planning, implementation and presentation of this activity to identify and resolve potential conflicts of interest for all persons in a position to control content.

PLANNING COMMITTEE & FACULTY

Planning Committee

David Drover, MD

Stanford University
Stanford, CA

Disclosure: Masimo, Grant/Research Support

Konrad Meissner, MD

University of Greifswald
Greifswald, GERMANY

Disclosure: None

Faculty

Manfred Blobner, MD

Technical University Munich
Munich, GERMANY

*Disclosure: MSD, Consultant,
Speaker, Grant/Research Support*

Emery Brown, MD, PhD

Harvard Medical School
Massachusetts Institute of
Technology
Cambridge, MA

Disclosure: None

Talmage Egan, MD

University of Utah
Salt Lake City, UT

*Disclosure: Johnson & Johnson,
Consultant, Grant/Research Support,
Scott Labs, Royalty*

Alexander Hannenberg, MD

Tufts University
Somerville, MA

Disclosure: None

Ross Kennedy, MD

University of Otago
Christchurch, NEW ZEALAND

Disclosure: GE Healthcare, Consultant

Ronald Makin

General Electric Company
Fitchburg, WI

Disclosure: GE Healthcare, Employee

John Sear, BSc, MBBS, PhD

University of Oxford
Oxford, UNITED KINGDOM

Disclosure: None

Steven Shafer, MD

Stanford University
Stanford, CA

Disclosure: Sedasys, Consultant

Michel Struys, MD, PhD

University of Groningen
THE NETHERLANDS

Disclosure: Draeger, Grant/Research Support

Moderators

David Drover, MD

Stanford University
Stanford, CA

Disclosure: Masimo, Grant/Research Support

Ken Johnson, MD

University of Utah
Salt Lake City, UT

Disclosure: Medvis, Stock Holder

Konrad Meissner, MD

University of Greifswald
Greifswald, GERMANY

Disclosure: None

SAVE THE DATE

23RD ANNUAL MEETING

Friday, October 10, 2014

New Orleans, LA

SCHEDULE OF EVENTS

7:00 – 8:00 **Breakfast**

8:00 – 8:05 **Welcome**
David Drover, MD

Session #1 **Theme: Pharmacology Update**
Moderator:
David Drover, MD

8:05 – 8:50 ***Sugammadex: Options and Risk of a First in Class Reversal Agent***
Manfred Blobner, MD

8:50 – 9:40 ***The Loss and Recovery of Consciousness and Associated EEG Signatures***
Emery Brown, MD, PhD

9:40 – 10:00 **Break**

Session #2A **Theme: Drug Delivery and Prediction**
Moderator:
Konrad Meissner, MD

10:00 – 10:40 ***Why Should I give Propofol by TCI? Rationale, Utility and Questions***
John Sear, BSc, MBBS, PhD

Session #2B **Theme: Prediction of Effect**
Moderator:
Konrad Meissner, MD

10:40 – 11:20 ***Interaction Models in Prediction of Effect***
Michel Struys, MD, PhD

11:20 – 11:45 ***Why Should We Use Devices Such as Navigator and Smart Pilot to Guide Our Anesthetic?***
Ross Kennedy, MD

11:45 – 12:10 ***Real Time Visualizations of Response Surface Models: A Demonstration***
Ronald Makin

12:10 – 13:25 **Lunch and Business Meeting**

Session #3 **Poster Session**

13:25 – 14:00 ***Moderated Poster Discussion***
ISAP Board

14:00 – 14:15 **Break**

Session #4 **Theme: Emerging Developments in Propofol Sedation by Non-Anesthesiologists**
Moderator: Ken Johnson, MD

14:15 – 15:00 ***An Introduction to Computer-Assisted Personalized Sedation (CAPS)***
Talmage Egan, MD

15:00 – 15:45 ***The Future of Sedation Procedures***
Steven Shafer, MD

15:45 – 16:30 ***Overview of Propofol Sedation Policy and Regulation***
Alexander Hannenberg, MD

16:30 – 17:00 ***Panel Discussion: Pros and Cons of the Non-Anesthesiologist Providing Sedation***
Talmage Egan, MD;
Alexander Hannenberg, MD; Steven Shafer, MD

17:00 – 18:00 **Reception**

ABSTRACTS

Abstract #	Abstract Title:	Presenting Author	Institution
1	Regulatory Considerations in the Design of A Propofol Closed-Loop TCI Pump Controller: Stability	Stephane Bibian, PhD	NeuroWave Systems, Inc
2	Performance of NSRI or Pupillary Dilatation Reflex to Predict Responses to Skin Incision	Valerie Billard, MD	Institut Gustave Roussy
3	Drug Interactions : Beyond the Hypnotic/Opioid Balance?	Marie Binczak, MD	Institut Gustave Roussy
4	Influence of Alprazolam Premedication on the Occurrence of Postoperative Obstructive Apnea	Eric Deflandre, MD, FCCP	Cabinet Medical ASTES & Clinique Saint-Luc de Bouge
5	Sevoflurane Preconditioning Induced-Neuroprotection is Associated with Restoring AKT Activity via CTMP Inhibition in Rats	Hailong Dong, PhD	Xijing Hospital
6	Aging-Related Plasticity of Brain Orexin System is Involved in the Delayed Emergence from Isoflurane Anesthesia in the Rat	Hailong Dong, PhD	Xijing Hospital
7	Efficient Assessment of Pregabalin Combined with Morphine Using in Patients with Neuropathic Cancer Pain	Zhi Dou, MS	The First Affiliated Hospital of Guangxi Medical University
8	Pharmacokinetics of Prophylactic Cefazolin in Parturients Undergoing Cesarean Section	Mohammed Elkomy, PhD	Stanford University
9	Pharmacokinetics of Ondansetron in Non-Pregnant Women and Parturients Undergoing Cesarean Section	Mohammed Elkomy, PhD	Stanford University
10	Loperamide Interacts with Uptake Transporters of the OATP Family	Konrad Meissner, MD	University of Greifswald
11	Severe Myoclonus Under Desflurane and Propofol TIVA	Pamela Flood, MD	University of California, San Francisco
12	GABAA Receptor Residue Beta-N265 on M2 is an Etomidate Binding Determinant	Stuart Forman, MD, PhD	Massachusetts General Hospital
13	Cysteine Substitutions Define State-Dependent Accessibility and Etomidate Binding Interactions in the Alpha-M1 Domain of GABAA Receptors	Stuart Forman, MD, PhD	Massachusetts General Hospital
14	Encapsulation of Dextrophan by Cucurbit[7]Urils	Raymond Glassenberg, MD	Northwestern University
15	Response to Noxious Stimuli in Closed-Loop Controlled Propofol Anesthesia with Target Controlled Infusion of Remifentanyl	Matthias Görges, PhD	University of British Columbia
16	Influence of The Method of PK and PD Modeling on the Objective Function and The PD Parameters	Laura Hannivoort, MD	University Medical Center Groningen, University of Groningen
17	Blood Gas Partition Coefficient of Propofol in Humans	Cyrril Hornuss, MD	Klinikum der Universität München
18	A Semi-Mechanical PK-PD Model for Rocuronium and Sugammadex to Quantify Covariate Effects and Enable Prediction of (Reversal) of Neuromuscular Block in Various Scenarios	Huub J Kleijn, MSc	Merck
19	An Economic Review of Published Clinical Trials 1980-2012 for Postoperative Atrial Fibrillation Prophylaxis in Cardiac Surgery	Michael Kot, MD	Cleveland Clinic
20	The Balanced Anaesthesia Pilot Study	Kate Leslie, MD	Royal Melbourne Hospital
21	Behavioral, Eeg and Synaptic Actions of Isoflurane in The Rat	Bruce Maciver, PhD	Stanford University
22	Effect-Site Concentration of Propofol During Emergence from Total Intravenous Anesthesia with or Without Epidural Anesthesia	Kensaku Ogawa, ME	National Defense Medical College
23	Suppression of Central Cx3Cr1 Signaling Alleviates Amyloid-Induced Memory Deficiency	Jiang Wu, MD	Cleveland Clinic
24	Association Between Fibromyalgia and Post-Operative Mortality in US Surgical Inpatients	Harpreet Singh, MD	Cleveland Clinic Foundation

ABSTRACTS (CONT.)

25	Clinical Assessment of Control Performance in Closed-Loop Anesthesia	Kousha Talebian, BASc	University of British Columbia
26	The Effect of Ketamine and Rocuronium on the Neurosense WAVCNS Index During Steady-State Anesthesia with Propofol and Remifentanyl	Hugo Vereecke, MD, PhD	University Medical Center Groningen, University of Groningen
27	Usability Evaluation of a Dual Closed-Loop Anesthesia System	J Mark Ansermino, FRCPC	University of British Columbia
28	Comparative Testing of Physicochemical Properties of Reformulated Opana ER and OxyContin	Frank Diana, PhD	Endo Pharmaceuticals, Inc
29	Trypsin-Labile Opioid Prodrugs for Extended-Release of Oxycodone and Hydromorphone	Steven Shafer, MD	Stanford University
30	Opioid Prodrug for Immediate-Release Hydrocodone	Steven Shafer, MD	Stanford University
31	Abuse Resistance of Trypsin-Labile Extended-Release Opioid Prodrugs	Steven Shafer, MD	Stanford University
32	Pharmacokinetics of A Trypsin-Labile Extended-Release Hydromorphone Prodrug in Healthy Volunteers	Steven Shafer, MD	Stanford University
33	Morphine and Hydromorphone Interact Differently with Uptake Transporters of The OATP Family	Anett Engel, PhD	University of Greifswald
34	Wake Up and Endoscope Insertion Depths as Measured by Sedline Monitor in Advanced Gastrointestinal Endoscopy	Amit Manjunath	University of Pennsylvania
35	Depth of Sedation in Upper GI Endoscopy	Joel Reihmer	University of Pennsylvania
36	Effectiveness of High Dose Remifentanyl in Preventing Coughing and Laryngospasm in Non-Paralyzed Patients for Advanced Bronchoscopic Procedures	Amit Manjunath	University of Pennsylvania

COMMERCIAL SUPPORT LEVELS

PLATINUM PLUS

Merck

www.merck.com

PLATINUM

Masimo

www.masimo.com

Draeger

www.draeger.com

**Sedasys, a division of
Ethicon Endo-Surgery, Inc, Inc
www.sedasys.com**